CORT Corcept Therapeutics Incorporated

63.62USD-2.09%Mkt Cap: 6.96B USDP/E: 47.83

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap6.96B USD
Enterprise Value6.75B USD
Revenue (TTM)963.65M USD
Gross Profit748.43M USD
Net Income (TTM)99.65M USD
Revenue/Share9.17 USD
Last Price63.62 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees730
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)47.83
P/E (Forward)12.77
PEG0.81
EV/EBITDA59.66
EV/Revenue7.00
P/S7.23
P/B8.35
EPS (TTM)1.33 USD
EPS (Forward)4.98 USD
52W Range
28.6637% of range124.01
52W High124.01 USD
52W Low28.66 USD
Profitability
Gross Margin98.30%
Oper. Margin11.51%
EBITDA Margin11.74%
Profit Margin13.09%
ROE15.38%
ROA11.91%
ROIC15.90%
ROCE6.68%
Growth
Revenue Growth64.00%
Earnings Growth531.30%
Cash Flow & Leverage
Operating CF142.00M USD
CapEx (TTM)211.00K USD
FCF Margin13.72%
FCF Yield1.90%
Net Debt-361.71M USD
Net Debt/EBITDA-3.20
Net Debt/FCF-2.74
Balance Sheet
Debt/Equity0.01
Current Ratio3.00
Quick Ratio2.71
Book Value/Sh7.62 USD
Cash/Share3.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)142.60 USD
Upside (mean)+124.1%
Target Range50.00 USD – 173.00 USD
50.00+124.1% to mean173.00
# Analysts5
Ownership
Shares Out.109.44M
Float97.81M
Insiders11.32%
Institutions74.47%
Short Interest
Short Ratio9.8d
Short % Float10.70%
Short % Out.8.34%
Shares Short9.13M
Short (prev mo.)8.54M
Technical
SMA 50101.01 (-37.0%)
SMA 20076.93 (-17.3%)
Beta0.56
S&P 52W Chg12.00%
Avg Vol (30d)1.13M
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)21.0
MACD-9.7621
MACD Signal-9.6314
MACD Hist.-0.1307
BB Upper90.70 USD
BB Middle75.97 USD
BB Lower61.23 USD
BB Width38.80%
ATR (14)4.868 USD
Vol Ratio (20d)0.80x

About Corcept Therapeutics (NASDAQ: CORT)

›

Corcept Therapeutics (NASDAQ: CORT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 730 employees.

The shares were at 63.62 USD on 20 November 2026, down 13.7% over 52 weeks. Its 52-week range is 28.66 USD to 124.01 USD: the price is 48.7% below the high and 122.0% above the low.

At a market capitalisation of 6.96B USD, it trades at 47.8 times trailing earnings and 12.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 44% for CORT.

Corcept Therapeutics reports return on equity of 15.4%, an operating margin of 11.5% and revenue up 64.0% year over year.

It holds more cash than debt, a net cash position of 361.71M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 142.60 USD is 124.1% above the current price. The next earnings report is expected on 24 February 2027.